Replies to post #95672 on Biotech Values

[mcbio]

Re: partnering of ACH-1625

Todays ACHN conference call was pretty definitive in the sense that mgmt seemed adamant they would partner. Obviously the QD was emphasized and it appears that they may do some additional QD cohorts because of the efficacy.

Management seemed adamant in the call today that they would partner ACH-1625, but I don't think they were clear as to whether that would be before the start of Phase 2a trials in September or sometime after. (I expect they'll partner before the start of Phase 2a based on prior clues, but that's just a guess on my part.) QD was the focus of most of the call today and I agree that it sounds like additional QD cohorts will be explored in the Phase 2a, although management was not absolutely firm in committing to that. I'll post my notes to today's call separately.